• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Chemokine Therapeutics to Present at BioContact Annual Global Healthcare Conference

Posted on: Monday, 1 October 2007, 09:00 CDT

Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that Dr. Bin Huang, Vice President of Corporate Development will be presenting at the BioContact Annual Conference in Quebec City, Canada on Thursday, October 4th, 2007. Dr. Huang will provide an overview of the Company and the Company's two lead drug candidates, CTCE-9908 for the treatment of cancer and CTCE-0214 for neutrophil mobilization both in human clinical trials.

BioContact is a biopharmaceutical partnership symposium gathering over 1200 participants from North America, Asia and Europe.

When: Thursday October 4th at 9:00 am (EST).

Website: www.biocontact.ca

About Chemokine Therapeutics Corp. (TSX: CTI)(OTCBB: CHKT)

Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 Contacts: Chemokine Therapeutics Corp. Mr. Don Evans Director of Public Relations (604) 822-0305 or 1-888-822-0305 (604) 822-0302 (FAX) Email: devans@chemokine.net Website: www.chemokine.net

SOURCE: Chemokine Therapeutics Corp.

Source: MARKET WIRE

More News in this Category